Business context and reporting period
Entity clarification: The supplied filing is AVROBIO, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed March 14, 2024. It is not a standalone Tectonic Therapeutic, Inc. 10-K. Tectonic is discussed because AVROBIO agreed to merge with it in January 2024.
AVROBIO had focused on hematopoietic stem cell gene therapies for rare diseases. In July 2023, it halted development of its programs and began exploring strategic alternatives. None of its remaining three candidates—Gaucher, Pompe and Fabry—was in active clinical development at the filing date. AVROBIO sold its cystinosis program to Novartis in June 2023 and discontinued its Hunter syndrome program.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $47.7 million | $72.2 million |
| General and administrative expense | $24.0 million | $33.2 million |
| Net income (loss) | $12.2 million | $(105.9) million |
| Net cash used in operating activities | $(63.2) million | $(97.2) million |
| Cash and cash equivalents at year-end | $98.0 million | $92.6 million |
| Total liabilities at year-end | $6.4 million | $28.6 million |
2023 net income included an $83.7 million gain on the cystinosis asset sale, net of transaction costs, and therefore does not indicate recurring profitability. Operating expenses totaled $71.7 million; margins are not meaningful because AVROBIO had no product revenue. Investing activities provided $85.1 million, primarily from the asset sale and equipment sales. Financing activities used $16.0 million, including repayment of the term loan. No debt remained on the year-end balance sheet. Cash plus restricted cash was $98.7 million.
Management stated that year-end cash and cash equivalents were expected to fund current planned operations and capital expenditure requirements for at least 12 months from the filing date. That statement is in the context of halted development and a pending strategic transaction. The company reported no off-balance-sheet arrangements. It had approximately $0.9 million of remaining minimum operating lease payments in 2024.
Material changes versus the prior year
- Net income improved by $118.0 million, chiefly because of the one-time cystinosis asset-sale gain; 2022 recorded a substantial net loss.
- R&D expense fell $24.5 million and G&A expense fell $9.3 million, reflecting reduced development activity, lower personnel and consulting costs, and restructuring; legal expense increased.
- Operating cash use declined by $34.0 million year over year, while the asset sale provided a major one-time source of investing cash.
- AVROBIO repaid and terminated its term loan in June 2023. Its workforce was substantially reduced, including further reductions in the second half of 2023.
Outlook, transaction, risks and unusual items
- Proposed merger: On January 30, 2024, AVROBIO agreed to acquire Tectonic through a merger, subject to stockholder approvals and other closing conditions. Tectonic’s business would become the combined company’s business. Investors agreed to private financings totaling approximately $130.7 million, including SAFE conversions.
- After the financings, estimated ownership was approximately 22.3% for pre-merger AVROBIO securityholders, 39.8% for former Tectonic securityholders and 38.0% for private-financing purchasers, subject to assumptions and adjustment. AVROBIO management estimated closing net cash at approximately $65–$75 million; the stated ownership estimate assumed about $65 million.
- The merger provides for a proposed 1-for-3 to 1-for-30 reverse stock split, subject to approval. AVROBIO stockholders would also receive non-transferable contingent value rights tied to qualifying proceeds from dispositions of pre-closing assets; payment is not assured, and the rights could expire valueless.
- If the merger does not close, AVROBIO may pursue other alternatives, including dissolution and liquidation. The filing describes potential termination fees of $2.7 million payable by AVROBIO or $4.9 million by Tectonic in specified circumstances, and up to $650,000 of expense reimbursement by AVROBIO in specified circumstances.
- A stockholder lawsuit filed in February 2024 challenges disclosures related to the merger; AVROBIO says it intends to defend the claims. Four stockholder demand letters also sought additional merger disclosures.
- Key risks include transaction failure or delay, dilution, reduced AVROBIO stockholder influence, continued cash burn, possible liquidation, Nasdaq listing compliance, and the substantial clinical, manufacturing, regulatory and intellectual-property risks associated with any future resumption of gene-therapy development.
- The filing reports no material legal proceedings at year-end, but separately discloses the post-year-end merger lawsuit. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2023. The auditor gave an unqualified opinion on the financial statements and reported no critical audit matters.
Most important facts for investors to verify
- Whether the merger and related private financings close, and the final exchange ratio, closing net cash and ownership percentages.
- Current cash, transaction expenses and expected cash runway, particularly if the merger is delayed or not completed.
- Reverse-split terms and Nasdaq listing status, plus the final CVR agreement terms and any asset-disposition proceeds.
- Whether the merger litigation or demand letters affect timing, disclosures or closing conditions.
- That 2023 reported profit primarily reflects the one-time asset sale, while the company had no product revenue and used $63.2 million of operating cash.